DVAX Dynavax Technologies Corporation
USHealthcareAs of 2026-02-11 16:00
Why DVAX matters now
Dynavax Technologies Corporation (DVAX) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.50 with +0.00% on the session and $1.82B in market capitalization; recent performance reads 1-month +0.00% and YTD +0.78%.
The latest financial table shown here is Q3 2025, with revenue of $94.9M, net income of $26.9M, and EPS of $0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 4.4%.
Additional event context on this page matters because analyst consensus is Hold with a median target of $29.00; recent insider activity includes Deep Track Biotechnology Master Fund, Ltd. filing U-Tender. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.40
P/S
5.51
EV/EBITDA
-75.99
DCF Value
$-22.27
FCF Yield
4.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.2%
Operating Margin
3.2%
Net Margin
-13.1%
ROE
-8.1%
ROA
-4.6%
ROIC
1.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $94.9M | $26.9M | $0.21 |
| Q2 2025 | $95.4M | $18.7M | $0.14 |
| Q1 2025 | $68.2M | $-96.1M | $-0.77 |
| Q4 2024 | $72.0M | $7.0M | $0.05 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$27.00
Target (Median)
$29.00
Target Range
$20.00 - $32.00
Trading Activity
Insider Trades
Related Stocks
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.93
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.